Millipore Sigma Vibrant Logo

553211 InSolution™ Rapamycin - Calbiochem

Overview

Replacement Information

Key Spec Table

Empirical Formula
C₅₁H₇₉NO₁₃

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
553211-1MG
Retrieving availability...
Fulfillment and Delivery Delayed
Fulfillment and Delivery Delayed
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      553211-500UG
      Retrieving availability...
      Fulfillment and Delivery Delayed
Fulfillment and Delivery Delayed
      In Stock 
      Discontinued
      Limited Quantities Available
      Availability to be confirmed
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 500 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity is a multiple of
          Maximum Quantity is
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          Catalogue Number553211
          Brand Family Calbiochem®
          SynonymsmTOR Inhibitor I
          References
          Product Information
          ATP CompetitiveN
          FormLiquid
          FormulationA 5 mM (500 µg/109 µl) solution of Rapamycin (Cat. No. 553210) in DMSO.
          Hill FormulaC₅₁H₇₉NO₁₃
          Chemical formulaC₅₁H₇₉NO₁₃
          Hygroscopic Hygroscopic
          ReversibleN
          Structure formula ImageStructure formula Image
          Quality LevelMQ100
          Applications
          Biological Information
          Primary TargetMammalian target of rapamycin (mTOR)
          Primary Target IC<sub>50</sub>50 pM inhibiting the mammalian target of rapamycin (mTOR) and blocking the subsequent activation of p70 S6 kinase
          Purity≥98% by TLC
          Physicochemical Information
          Cell permeableN
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped with Blue Ice or with Dry Ice
          Toxicity Irritant
          Storage -20°C
          Protect from Light Protect from light
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial use, aliquot and freeze (-20°C).
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications
          Global Trade Item Number
          Catalogue Number GTIN
          553211-1MG 04055977193541
          553211-500UG 04055977193558

          Documentation

          InSolution™ Rapamycin - Calbiochem SDS

          Title

          Safety Data Sheet (SDS) 

          InSolution™ Rapamycin - Calbiochem Certificates of Analysis

          TitleLot Number
          553211

          Citations

          Title
        • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
        • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
        • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
        • Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision09-September-2008 RFH
          SynonymsmTOR Inhibitor I
          DescriptionSelectively inhibits the phosphorylation and activation of p70 S6 kinase (IC50 = 50 pM). Prevents the translational activation of IGF-II. Also prevents resting T-cells from entering the cell cycle, but does not directly arrest cell cycle progression. Shown to inhibit later signaling events, such as p110Rb phosphorylation, p34cdc2 kinase activation, and cyclin A synthesis. Exhibits strong binding to FK-506 binding proteins. Also reported to induce apoptosis in a murine B-cell line, to inhibit lymphokine-induced cell proliferation at the G1 phase, and to irreversibly arrest Saccharomyces cerevisiae cells in the G1 phase.
          FormLiquid
          FormulationA 5 mM (500 µg/109 µl) solution of Rapamycin (Cat. No. 553210) in DMSO.
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₅₁H₇₉NO₁₃
          Structure formulaStructure formula
          Purity≥98% by TLC
          Storage Protect from light
          -20°C
          Hygroscopic
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial use, aliquot and freeze (-20°C).
          Toxicity Irritant
          Citation
        • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
        • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
        • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.